Оптимизация терапии диспластических ВПЧ-ассоциированных процессов

Abstract

The objective: to determine the level of risk of developing clinical forms of papilloma virus infection (PVI) and possible ways of treatment and prevention of dysplastic diseases caused by human papilloma virus (HPV). Patients and methods. The study included 90 patients with diagnosed of oncogenic strains of HPV 16-68 (using the method of genotyping). The patients were divided into 3 groups in accordance with treatment aimed at the pathogenetic mechanisms of development of PVI and with the aim of reducing viral load, clinical manifestations and possible elimination of HPV. The first (I) group - 30 people - were given an injection of a-interferon 2b 3 mln per day, 10 injections; course dose - 30 mln. The course repeated in case of positive results of HPV (pre-selected strains) according to the same scheme or at intervals of 1-2 days; course dose - 30 mln. Second (II) group - 30 people - received indole-3-carbinol with epigallocatechin-3-gallate (I3C+EGCG) - a drug Epigalin® in the dose of 400 mg I3C and 90 mg EGCG (2 capsules per day). The course of taking in Epigalin® continued 6 months. The control group included patients in the amount of 30 people who did not receive specific oncoprotective immunomodulatory therapy. Results. As a result of the therapy after 3 months in group I patients who had received a-interferon-2b, elimination of HPV was observed in 76.2% of cases; in group II, treated with Epigalin® – in 86.4% of cases and in the control group not receiving additional metabolic therapy in 24% of cases. After 6 months in group I elimination of HPV was 92.6%, in group II it was 95.8%, which also shows better results of the effectiveness of interventions using I3C+EGCG – Epigalin®. Among patients treated in the period of rehabilitation after diathermocoagulation (DEC) drug Revitaxa (hyaluronic acid, tea tree, calendula, aloe vera, centella), epithelialization occurred on 7-10 days earlier, and without rough scar deformation. Conclusion. The use of metabolic immune replacement therapy of papillomavirus infection shows better results than the isolated use of electrosurgical (radio wave) treatment of dysplasia. The drug Epigalin® (a combination of 400 mg I3C and 90 mg EGCG) is an effective oncoprotective, normalizing the balance of estrogen with the drug, contributing to the elimination of HPV. The combination of the drug Epigalin® with a comprehensive reparative and antiseptic drug Revitaxa (suppositories) is optimal in cases of surgical treatment of lesions caused by HPV. Key words: human papilloma virus, elimination, interferon, Epigalin®, Revitaxa.